Viking's GLP-1 drug, VK2735, is currently in the midst of multiple clinical trials. The company is evaluating whether it can be taken monthly for maintenance dosing. 10 stocks we like better than ...
The anti-obesity drug market is getting crowded. Many healthcare companies are working on their own GLP-1 drugs in an effort to take market share, which could amount to billions of dollars in revenue.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results